BC Extra | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

The widely anticipated release of negotiated additions to the National Reimbursement Drug List by China’s National Medical Insurance Administration came on Nov. 28, with Innovent’s Tyvyt the lone anti-PD-1 mAb to make the cut. In...
BC Extra | Aug 28, 2019
Politics & Policy

Aug. 28 P&P Quick Takes: Liver failure warning for HCV drugs; plus FDA guidances and more

Liver failure linked to HCV drugs  FDA said it has identified 63 incidences of worsening liver function, including cases of liver failure and death, in patients with liver impairment taking HCV drugs Mavyret glecaprevir/pibrentasvir from...
BC Extra | Jun 27, 2019
Politics & Policy

June 26 P&P Quick Takes: FDA solicits comments on transparency programs; plus Louisiana’s HCV drug model and more

FDA seeking feedback on clinical data pilot  FDA is seeking feedback on two programs designed to improve clarity and transparency related to drug approval decisions. Under the Clinical Data Summary Report pilot, launched in January...
BC Extra | Apr 26, 2019
Company News

Express Scripts excludes Lilly's low cost insulin generic from preferred formulary

Express Scripts Holding Co. (NASDAQ:ESRX) excluded from its 2019 preferred formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs. PBMs and insurance companies typically require...
BC Extra | Mar 26, 2019
Company News

Louisiana picks Gilead's generics unit for HCV subscription model

Louisiana has chosen to partner with Gilead's generics subsidiary to access a generic version of HCV drug Epclusa sofosbuvir/velpatasvir through a subscription-based model. The state's Department of Health and Department of Corrections said the deal...
BC Extra | Mar 5, 2019
Company News

Lilly offers cheaper insulin, pressuring competitors

Lilly will offer a new, lower cost insulin that is substitutable for Humalog at pharmacies. While at least one patient group says it's not enough, the move puts pressure on the pharma’s competitors. Months of...
BC Week In Review | Jan 25, 2019
Clinical News

Cocrystal reports SVR12 rate of 67% for CC-31244 regimen

Cocrystal Pharma Inc. (NASDAQ:COCP) reported preliminary data from an open-label, U.S. Phase IIa trial showing that eight of 12 (67%) evaluable patients with treatment-naïve HCV genotype 1 infection who received 400 mg oral CC-31244 plus...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Dec 7, 2018
Clinical News

China approves Descovy, Harvoni, Hemlibra

China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche...
BC Extra | Dec 4, 2018
Company News

China approves Descovy, Harvoni, Hemlibra

China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche...
Items per page:
1 - 10 of 81